Risk assessment of complications using clot wave form analysis and M2BPGi in patients with cirrhosis

Phase 1

• Conditions: Bleeding complications such as variceal bleeding, intraabdominal bleeding, intracerebral bleeding; Bleeding, cirrhosis

• Registration Number: TCTR20200730001
• Lead Sponsor: &#45

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-30
• Study Completion: 2022-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

1) Age > 18 years
2) Chronic liver disease from any causes.
3) Advanced liver fibrosis (≥ stage 3) or cirrhosis diagnosed by imaging, histology with/without HCC

Exclusion Criteria

1) Hematologic disease
2) Taking anticoagulants eg. warfarin, enoxaparin, new oral anticoagulants
3) History of endoscopic variceal ligation or sclerosis
4) HIV infection
5) post transplantation

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Bleeding baseline, 6, 12, 18, 24 months Clot waveform analysis, M2BPGi

Secondary Outcome Measures

Name	Time	Method
Other complications of liver cirrhosis baseline, 6, 12, 18, 24 months Clot waveform analysis, M2BPGi, Fibroscan